Zobrazeno 1 - 10 of 70 pro vyhledávání: '"Michael A. Bolognese"'
1
Akademický článek
Skeletal responses to romosozumab after 12 months of denosumab
Autor: Michael R. McClung, Michael A. Bolognese, Jacques P. Brown, Jean‐Yves Reginster, Bente L. Langdahl, Yifei Shi, Jen Timoshanko, Cesar Libanati, Arkadi Chines, Mary K. Oates
Publikováno v: JBMR Plus, Vol 5, Iss 7, Pp n/a-n/a (2021)
ABSTRACT Romosozumab, a monoclonal anti‐sclerostin antibody that has the dual effect of increasing bone formation and decreasing bone resorption, reduces fracture risk within 12 months. In a post hoc, exploratory analysis, we evaluated the effects
Externí odkaz: https://doaj.org/article/e0b2fb4a5a8b4695a0b58acc5354c9e5
Zobrazit plný text záznamu
2
Akademický článek
Influence of subject discontinuation on long-term nonvertebral fracture rate in the denosumab FREEDOM Extension study
Autor: Jonathan D. Adachi, Henry G. Bone, Nadia S. Daizadeh, Paula Dakin, Socrates Papapoulos, Peyman Hadji, Chris Recknor, Michael A. Bolognese, Andrea Wang, Celia J. F. Lin, Rachel B. Wagman, Serge Ferrari
Publikováno v: BMC Musculoskeletal Disorders, Vol 18, Iss 1, Pp 1-8 (2017)
Abstract Background Denosumab treatment for up to 8 years in the FREEDOM study and Extension was associated with low fracture incidence. It was not clear whether subjects who discontinued during the study conduct had a higher risk of fracture than th
Externí odkaz: https://doaj.org/article/82d84359d66240d5b137491968ed5b27
Zobrazit plný text záznamu
3
Akademický článek
AI-Generated Graduate Medical Education Content for Total Joint Arthroplasty: Comparing ChatGPT Against Orthopaedic Fellows
Autor: Ryan DeCook, BS, Brian T. Muffly, MD, Sania Mahmood, MD, Christopher T. Holland, MD, MS, Ayomide M. Ayeni, BS, Michael P. Ast, MD, Michael P. Bolognese, MD, George N. Guild, III, MD, Neil P. Sheth, MD, Christian A. Pean, MD, MS, Ajay Premkumar, MD, MPH
Publikováno v: Arthroplasty Today, Vol 27, Iss , Pp 101412- (2024)
Background: Artificial intelligence (AI) in medicine has primarily focused on diagnosing and treating diseases and assisting in the development of academic scholarly work. This study aimed to evaluate a new use of AI in orthopaedics: content generati
Externí odkaz: https://doaj.org/article/a5d4ffdd5d844cdd93df9cf7fa3b7d46
Zobrazit plný text záznamu
5
A single dose of zoledronate preserves bone mineral density for up to 2 years after a second course of romosozumab
Autor: Paul D Meisner, Andreas Grauer, Yifei Shi, Michael A. Bolognese, Michael R. McClung, Bente L. Langdahl, Judy Maddox, Jacques P. Brown, Jean-Yves Reginster, Maria Rojeski
Publikováno v: McClung, M R, Bolognese, M A, Brown, J P, Reginster, J Y, Langdahl, B L, Maddox, J, Shi, Y, Rojeski, M, Meisner, P D & Grauer, A 2020, ' A single dose of zoledronate preserves bone mineral density for up to 2 years after a second course of romosozumab ', Osteoporosis International, vol. 31, no. 11, pp. 2231-2241 . https://doi.org/10.1007/s00198-020-05502-0
Osteoporosis International
Summary This phase 2 study evaluated the efficacy and safety of transitioning to zoledronate following romosozumab treatment in postmenopausal women with low bone mass. A single dose of 5 mg zoledronate generally maintained the robust BMD gains accru
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ed6aac61337103cd7cadb5824091c5c7
https://doi.org/10.1007/s00198-020-05502-0
Zobrazit plný text záznamu
6
Skeletal responses to romosozumab after 12 months of denosumab
Autor: Yifei Shi, Cesar Libanati, Mary Oates, Bente L. Langdahl, Jacques P. Brown, Michael R. McClung, Jean-Yves Reginster, Arkadi Chines, Jen Timoshanko, Michael A. Bolognese
Publikováno v: McClung, M R, Bolognese, M A, Brown, J P, Reginster, J Y, Langdahl, B L, Shi, Y, Timoshanko, J, Libanati, C, Chines, A & Oates, M K 2021, ' Skeletal responses to romosozumab after 12 months of denosumab ', JBMR Plus, vol. 5, no. 7, e10512 . https://doi.org/10.1002/jbm4.10512
JBMR Plus, Vol 5, Iss 7, Pp n/a-n/a (2021)
JBMR Plus
Romosozumab, a monoclonal anti‐sclerostin antibody that has the dual effect of increasing bone formation and decreasing bone resorption, reduces fracture risk within 12 months. In a post hoc, exploratory analysis, we evaluated the effects of romoso
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::57927fa2e190f89276c23a7996a5ab29
https://pure.au.dk/portal/da/publications/skeletal-responses-to-romosozumab-after-12-months-of-denosumab(8a0ae335-220b-47cd-bd6c-c450d8378287).html
Zobrazit plný text záznamu
9
Effects of 24 Months of Treatment With Romosozumab Followed by 12 Months of Denosumab or Placebo in Postmenopausal Women With Low Bone Mineral Density: A Randomized, Double-Blind, Phase 2, Parallel Group Study
Autor: Michael A. Bolognese, Jose R. Zanchetta, Michael R. McClung, Andreas Grauer, Jacques P. Brown, Sarah Bray, Judy Maddox, John Caminis, Henry G. Bone, Adolfo Diez-Perez, Stefan Goemaere, Paul D Meisner, Heinrich Resch
Publikováno v: Journal of Bone and Mineral Research. 33:1397-1406
Over 12 months, romosozumab increased bone formation and decreased bone resorption, resulting in increased bone mineral density (BMD) in postmenopausal women with low BMD (NCT00896532). Herein, we report the study extension evaluating 24 months of tr
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e99aa8bc8aa692a3ae7af3bd319f1699
https://doi.org/10.1002/jbmr.3452
Zobrazit plný text záznamu
10
Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial
Autor: Jose Fernando Molina, Cesar Libanati, Fabio E Massari, Michael A. Bolognese, Eva Dokoupilova, Andreas Grauer, Joel S. Finkelstein, Nadia Daizadeh, Klaus Engelke, Jorge Malouf, Daria B. Crittenden, Stefan Goemaere, Judy Maddox, Harry K. Genant, Bente L. Langdahl, Peter L. Lakatos, Lars Hyldstrup, Jacques P. Brown, Tony M. Keaveny, Maria Rosa Ulla, David L. Kendler, Esteban Jódar-Gimeno
Publikováno v: Langdahl, B L, Libanati, C, Crittenden, D B, Bolognese, M A, Brown, J P, Daizadeh, N S, Dokoupilova, E, Engelke, K, Finkelstein, J S, Genant, H K, Goemaere, S, Hyldstrup, L, Jodar-Gimeno, E, Keaveny, T M, Kendler, D, Lakatos, P, Maddox, J, Malouf, J, Massari, F E, Molina, J F, Ulla, M R & Grauer, A 2017, ' Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy : a randomised, open-label, phase 3 trial ', Lancet, vol. 390, no. 10102, pp. 1585-1594 . https://doi.org/10.1016/S0140-6736(17)31613-6
Background: Previous bisphosphonate treatment attenuates the bone-forming effect of teriparatide. We compared the effects of 12 months of romosozumab (AMG 785), a sclerostin monoclonal antibody, versus teriparatide on bone mineral density (BMD) in wo
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::251efe9b027f857a6e77366dde2e6628
https://doi.org/10.1016/s0140-6736(17)31613-6
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje